These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10935691)

  • 21. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
    Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
    Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group.
    Cooper ER; Nugent RP; Diaz C; Pitt J; Hanson C; Kalish LA; Mendez H; Zorrilla C; Hershow R; Moye J; Smeriglio V; Fowler MG
    J Infect Dis; 1996 Dec; 174(6):1207-11. PubMed ID: 8940210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrapartum and neonatal zidovudine treatment in reduction of perinatal HIV-1 transmission in Bangkok.
    Thaithumyanon P; Thisyakorn U; Limpongsanurak S; Chaithongwongwatthana S; Punnahitanon S; Ubolyam S; Phanuphak P; Ruxrungtham K; Virutamasen P
    J Med Assoc Thai; 2001 Sep; 84(9):1229-34. PubMed ID: 11800293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of zidovudine treatment in late pregnancy on HIV-1 in utero transmission.
    Taneepanichskul S; Sirinavin S; Phuapradit W; Chaturachinda K
    Aust N Z J Obstet Gynaecol; 1997 Aug; 37(3):329-31. PubMed ID: 9325519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission.
    Bhoopat L; Khunamornpong S; Lerdsrimongkol P; Sirivatanapa P; Sethavanich S; Limtrakul A; Gomutbuthra V; Kajanavanich S; Thorner PS; Bhoopat T
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):545-50. PubMed ID: 16284530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrapartum zidovudine infusion alone failed to reduce both maternal HIV-1 viral load and HIV-1 infection in infant.
    Limpongsanurak S; Thaithumyanon P; Thisyakorn U; Ruxrungtham K; Chaithongwongwatthana S; Kongsin P; Tarounotai U; Chantheptaewan N; Triratwerapong T; Ubolyam S; Phanuphak P
    J Med Assoc Thai; 2001 May; 84(5):611-6. PubMed ID: 11560207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
    Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
    J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women.
    Melvin AJ; Burchett SK; Watts DH; Hitti J; Hughes JP; McLellan CL; King PD; Johnson EJ; Williams BL; Frenkel LM; Coombs RW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):232-6. PubMed ID: 9117455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone.
    Simpson BJ; Shapiro ED; Andiman WA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):145-52. PubMed ID: 9052723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants.
    Prasitwattanaseree S; Lallemant M; Costagliola D; Jourdain G; Mary JY
    Antivir Ther; 2004 Apr; 9(2):179-85. PubMed ID: 15134179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.
    Dryden-Peterson S; Shapiro RL; Hughes MD; Powis K; Ogwu A; Moffat C; Moyo S; Makhema J; Essex M; Lockman S
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):428-36. PubMed ID: 21266910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal characteristics associated with antenatal, intrapartum, and neonatal zidovudine use in four US cities, 1994-1998.
    Orloff SL; Bulterys M; Vink P; Nesheim S; Abrams EJ; Schoenbaum E; Palumbo P; Steketee RW; Simonds RJ;
    J Acquir Immune Defic Syndr; 2001 Sep; 28(1):65-72. PubMed ID: 11579279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.
    Sutthent R; Chokephaibulkit K; Piyasujabul D; Vanprapa N; Roogpisuthipong A; Chaisilwatana P
    J Clin Virol; 2002 Jul; 25(1):47-56. PubMed ID: 12126721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. New York City Perinatal HIV Transmission Collaborative Study Group.
    Abrams EJ; Matheson PB; Thomas PA; Thea DM; Krasinski K; Lambert G; Shaffer N; Bamji M; Hutson D; Grimm K
    Pediatrics; 1995 Sep; 96(3 Pt 1):451-8. PubMed ID: 7651777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human immunodeficiency virus infection in pregnant women, transmission and zidovudine therapy.
    Rovira MT; Antorn MT; Payá A; Castellanos E; Mur A; Carreras R
    Eur J Obstet Gynecol Reprod Biol; 2001 Jul; 97(1):46-9. PubMed ID: 11435008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods.
    Kuhn L; Abrams EJ; Weedon J; Lambert G; Schoenbaum EE; Nesheim SR; Palumbo P; Vink PE; Bulterys M
    J Infect Dis; 2000 Jul; 182(1):104-11. PubMed ID: 10882587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 viral load and other risk factors for mother-to-child transmission of HIV-1 in a breast-feeding population in Cote d'Ivoire.
    Jamieson DJ; Sibailly TS; Sadek R; Roels TH; Ekpini ER; Boni-Ouattara E; Karon JM; Nkengasong J; Greenberg AE; Wiktor SZ
    J Acquir Immune Defic Syndr; 2003 Dec; 34(4):430-6. PubMed ID: 14615662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus.
    MMWR Recomm Rep; 1994 Aug; 43(RR-11):1-20. PubMed ID: 7913986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.